Denial of the Motion to Dismiss in Northwest Biotherapeutics Lawsuit Against Seven Wall Street Market Makers for Spoofing Would be a Major Catalyst for the Company
Smith on Stocks Blog
by Larry Smith
2w ago
Key Points: I believe that the lawsuit will be allowed to go to discovery before or around mid-year. This will allow access to the trading records and computer algorithms used by market makers to spoof NWBO’s stock. This information will dramatically illustrate that Northwest has been the subject of a decade long stock manipulation scheme that has resulted in its penny stock trading status. Institutional investors can seldom invest in penny stocks. They also are perplexed as to why NWBO with a drug, DCVax-L, about to be approved for glioblastoma is trading at such a depressed level. Something ..read more
Visit website
Highly Probable UK Approval of DCVax-L in 1H, 2024 Would Be a Crowning Achievement for Northwest Biotherapeutics
Smith on Stocks Blog
by Larry Smith
2M ago
Key Points: On December 21, 2023, NWBO announced that it had submitted its MAA seeking regulatory approval for DCVax-L in the UK. The Company requested that MHRA review DCVax-L using the accelerated pathway and, in this report, I go over the reasons why I think the MHRA will do so. (The section in this report titled “Under the UK’s Early Access to Medicines Program, MHRA Review Could Be Swift” explains my thinking in detail.) Under the accelerated pathway, the MHRA commits to reviewing the application in 150 business days or less. This indicates a decision on approval at the latest could come ..read more
Visit website
Northwest Biotherapeutics: CEO Linda Powers’ Brilliant Manufacturing Strategy Has Created Enormous Shareholder Value
Smith on Stocks Blog
by Larry Smith
1y ago
Acronyms Used in This Report MHRA    Medicines and Healthcare products Regulatory Agency is the United Kingdom regulatory counterpart to FDA. The two agencies have a close, collegial working relationship. Approval of DCVax-L by MHRA would carry great weight in the FDA’s decision making GMP   Good Manufacturing Practice is a system required by regulatory agencies for ensuring that drugs are consistently manufactured according to carefully defined quality standards. ​​Guidelines address issues such as process validation, quality assurance assays, record keeping, personnel qualific ..read more
Visit website
Why I Believe Northwest Biotherapeutics Has Been and Continues to be the Subject of a Powerful Stock Manipulation Scheme
Smith on Stocks Blog
by Larry Smith
1y ago
DCVax-L Impressive Phase 3 Results Are Validated by Independent, Expert Scientists and Physicians; Supports Strong Upward Stock Move The final results of the phase 3 trial of DCVax-L were first released on May 10 at the New York Academy of Sciences conference. They were extremely encouraging showing that glioblastoma (GBM) patients treated with DCVax-L plus standard of care experienced an impressive increase in survival when compared to what is now achieved with standard of care alone. However, trial results reported by a company are always viewed with caution until they are validated by a pee ..read more
Visit website
Explanation of How Adam Feuerstein Has Egregiously Misrepresented the Results of the Phase 3 Trial of DCVax-L
Smith on Stocks Blog
by Larry Smith
1y ago
Executive Summary I have tried to make this report as short and readable as possible so that in many cases I provide links to a previous article I have written or other pertinent data, rather than recreating the information in this report. So, you will find lots of links. The intent is to give the reader my conclusions in short form in this executive summary, but also to provide access to in-depth information for those seeking more detail. Adam Feuerstein and his employer, Stat News, continue to falsely allege that the phase 3 trial of DCVax-L failed. This is a jaw dropping accusation given th ..read more
Visit website
Northwest Biotherapeutics; Journal of the American Medical Association (JAMA) Peer Reviewed Article on DCVax-L (murcidencel).
Smith on Stocks Blog
by Larry Smith
1y ago
Overview This article puts into perspective the importance of a peer reviewed article on the Phase 3 Trial of murcidencel (better known as DCVax-L) that was published today in the Journal of the American Medical Association. This is a landmark event in which independent experts in an exhaustive process (which I will shortly describe) resoundingly validated previously reported clinical study findings. Here is the link to the article. The major findings presented in the JAMA article are consistent with those presented at the New York Academy of Sciences on May 10, 2022 although there is muc ..read more
Visit website
Northwest Biotherapeutics’ Day Has Come at Last
Smith on Stocks Blog
by Larry Smith
1y ago
I’m Back Earlier this year I decided to end subscriptions to SmithOnStocks.com. Researching and writing articles on biotechnology companies required a significant amount of time and effort that detracted from other things that I wanted to do. I am very curious by nature and get genuinely excited when learning new things. My interests include biology, of course, which drives the biotechnology and pharma companies that I focused on in my blog, but it doesn’t end there. I now spend anywhere from four to eight hours a day studying all manner of interesting subjects such as anthropology, history, p ..read more
Visit website
Presentation of DCVax-L Results from ASCO by Dr. Keyoumers Ashkan
Smith on Stocks Blog
by Larry Smith
1y ago
Here is the link to a video from ASCO in which Dr. Keyoumers Ashkan summarized the results of the phase 3 trial of DCVax-L in newly diagnosed and recurrent glioblastoma. He is the clinical lead for neuro-oncology at King's College Hospital in the UK.and heads the Neuroscience Clinical Trial Unit.  Dr. Ashkan is one of the most respected neurosurgeons in the UK and Kings College is the premier teaching hospital in the UK. He was the chief investigator in the European segment of the phase 3 DCVax-L trial. Needless to say, these are impeccable credentials. Dr. Ashkan believes that DCVax-L is ..read more
Visit website
Northwest Biotherapeutics: Adam Feuerstein Investigates Adam Feuerstein’s Understanding of Dendritic Cell Vaccines
Smith on Stocks Blog
by Larry Smith
1y ago
Key Conclusion Let me ask you a question? If F-stein is trying to convince you that DCVax-L has no chance of being effective in glioblastoma multiforme (GBM), wouldn’t you expect him to have a good understanding of the biological basis for the product, its mechanism of action and how it is manufactured (especially the case for a living cell product)? Of course you would. Failing this, everything else he says is meaningless or highly questionable. This report unequivocally establishes that Adam Feuerstein has no such understanding. In searching through the plethora of articles he has written on ..read more
Visit website
Adam Feuerstein Is Facing a Firestorm of Criticism for His Misrepresentation of Results in the Phase 3 Study of DCVax-L in Glioblastoma Multiforme; A Practicing GBM Physician Chastises Him
Smith on Stocks Blog
by Larry Smith
2y ago
F-stein Challenges Members of the Oncology Community Who Treat Glioblastoma Multiforme Adam Feuerstein has thrown down the gauntlet in alleging that over 40 practicing oncologists who participated in the phase 3 trial of DCVax-L have misrepresented the findings. The results of the phase 3 trial were presented at the New York Academy of Science on May 10 and the physician participants who conducted the trial had to sign affidavits attesting to the integrity of the results shown in the paper. The key conclusions as presented by one of the clinical trial investigators were that DCVax-L was very s ..read more
Visit website

Follow Smith on Stocks Blog on FeedSpot

Continue with Google
Continue with Apple
OR